UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 145

Sortiert nach

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

Journal of antimicrobial chemotherapy, 2015-10, Vol.70 (10), p.2862-2869

2015

Link zum Volltext

Verfügbarkeit prüfen

Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models

Diagnostic microbiology and infectious disease, 2021-04, Vol.99 (4), p.115292-115292, Article 115292

2021

Link zum Volltext

Verfügbarkeit prüfen

Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia

European journal of clinical pharmacology, 2020-03, Vol.76 (3), p.349-361

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

Antimicrobial agents and chemotherapy, 2019-08, Vol.63 (8)

2019

Link zum Volltext

Verfügbarkeit prüfen

Antibody responses of SARS-CoV-2 vaccines amongst health care workers in a tertiary care hospital in Tripura, India: A cross-sectional study

Indian journal of community medicine, 2022-10, Vol.47 (4), p.583-586

2022

Link zum Volltext

Verfügbarkeit prüfen

Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria

Paediatric drugs, 2021-09, Vol.23 (5), p.465-484

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa

mBio, 2024-02, Vol.15 (2), p.e0316523-e0316523

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2015-08, Vol.21 (8), p.551-558

2015

Link zum Volltext

Verfügbarkeit prüfen

30 Determining a potential alternative empirical antibiotic regimen for the treatment of neonatal sepsis in low- and middle-income settings using pre-clinical in vitro techniques

Clinical infection in practice, 2022-09, Vol.15, p.100191, Article 100191

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment

Journal of clinical pharmacology, 2017-02, Vol.57 (2), p.211-218

2017

Link zum Volltext

Verfügbarkeit prüfen

Avibactam Pharmacokinetic/Pharmacodynamic Targets

Antimicrobial agents and chemotherapy, 2018-06, Vol.62 (6)

2018

Link zum Volltext

Verfügbarkeit prüfen

Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring Enterobacteriaceae in Murine Infection Models"

Antimicrobial agents and chemotherapy, 2021-01, Vol.65 (2)

2021

Link zum Volltext

Verfügbarkeit prüfen

Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST)

Journal of clinical microbiology, 2022-03, Vol.60 (3), p.e0027621-e0027621

2022

Link zum Volltext

Verfügbarkeit prüfen

Upregulation of the Maturation-Inducing Steroid Membrane Receptor in Spotted Seatrout Ovaries by Gonadotropin During Oocyte Maturation and Its Physiological Significance

Biology of reproduction, 2001-01, Vol.64 (1), p.21-29

2001

Link zum Volltext

Verfügbarkeit prüfen

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections

Journal of antimicrobial chemotherapy, 2019-02, Vol.74 (2), p.425-431

2019

Link zum Volltext

Verfügbarkeit prüfen

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia

Antimicrobial agents and chemotherapy, 2019-04, Vol.63 (4)

2019

Link zum Volltext

Verfügbarkeit prüfen

Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam

Antimicrobial agents and chemotherapy, 2020-03, Vol.64 (4)

2020

Link zum Volltext

Verfügbarkeit prüfen

Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation

European journal of clinical pharmacology, 2024-04, Vol.80 (4), p.529-543

2024

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae

Antimicrobial agents and chemotherapy, 2020-05, Vol.64 (6)

2020

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers

Drugs in R&D, 2018-09, Vol.18 (3), p.221-230

2018

Link zum Volltext

Verfügbarkeit prüfen

Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential

Drug metabolism and disposition, 2014-05, Vol.42 (5), p.932

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance

Antimicrobial agents and chemotherapy, 2022-04, Vol.66 (4), p.e0218121-e0218121

2022

Link zum Volltext

Verfügbarkeit prüfen

Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam

Journal of clinical pharmacology, 2014-03, Vol.54 (3), p.331-340

2014

Link zum Volltext

Verfügbarkeit prüfen

Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility

Clinical microbiology and infection, 2020-12, Vol.26 (12), p.1692-1693

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae

Antimicrobial agents and chemotherapy, 2020-10, Vol.64 (11)

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(127)

Publikationsform

Sprache

Englisch
(143)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(95)
Life Sciences & Biomedicine
(75)
Humans
(43)
Pharmacology & Pharmacy
(29)
Male
(27)
Microbiology
(26)
Female
(23)
Pediatrics
(16)
Microbial Sensitivity Tests
(15)
Adult
(14)
Infant, Newborn
(14)
Pharmacokinetics
(14)
Physical Sciences
(14)
Animals
(13)
Infectious Diseases
(12)
Anti-Bacterial Agents - Pharmacokinetics
(11)
Chemistry
(11)
Middle Aged
(10)
Pneumonia
(10)
Young Adult
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models

Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia

Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

Antibody responses of SARS-CoV-2 vaccines amongst health care workers in a tertiary care hospital in Tripura, India: A cross-sectional study

Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria

Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa

Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers

30 Determining a potential alternative empirical antibiotic regimen for the treatment of neonatal sepsis in low- and middle-income settings using pre-clinical in vitro techniques

Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment

Avibactam Pharmacokinetic/Pharmacodynamic Targets

Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring Enterobacteriaceae in Murine Infection Models"

Update from the European Committee on Antimicrobial Susceptibility Testing (EUCAST)

Upregulation of the Maturation-Inducing Steroid Membrane Receptor in Spotted Seatrout Ovaries by Gonadotropin During Oocyte Maturation and Its Physiological Significance

Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia

Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam

Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation

Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae

Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers

Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential

Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance

Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam

Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility

Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae

Suchergebnisse filtern